



Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting

La Chaux-de-Fonds, Switzerland, Apr. 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and RP10107, a novel and potent glutaminase inhibitor in hematological malignancies and solid tumors.

--- Three preclinical poster presentations highlight the potential of RP4010 and RP10107 alone and in combination with approved drugs for treating hematological malignancies and solid tumors.

About RP4010:

RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers. Aberrant CRAC channel activity has been linked to various autoimmune disorders and certain cancers via the NFAT pathway. In addition, the blockage of store-operated calcium entry (SOCE) by a CRAC channel inhibitor could suppress tumor growth through a number of mechanisms, including the inhibition of calcium-dependent activation of Akt/NF- κ B and ERK 1/2 pathways. A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Lymphomas is currently ongoing in USA (ClinicalTrials.gov Identifier: NCT03119467).

About RP10107:

RP10107 is a novel and potent glutaminase inhibitor in late preclinical development with demonstrated preclinical activity in a broad range of cancers. Glutaminase enzyme, which converts glutamine to glutamate, has been identified as a critical choke point in the utilization of glutamine by cancer cells. These research findings point to the utility of a glutaminase inhibitor in treating glutamine-dependent cancers either alone or in combination with standard of care drugs.

Details of the poster presentations:

-- Poster Title: Store-operated calcium signaling is an effective therapeutic target in AML

- Session Category: Experimental and Molecular Therapeutics
- Session Title: New Targets 1
- Session Date & Time: Monday, April 16, 2018; 8:00 AM – 12:00 PM
- Location: McCormick Place South, Exhibit Hall A, Poster Section 40
- Poster Board Number: 13

-- Poster Title: Synergistic effects of glutaminase and proteasome inhibition in multiple myeloma cell lines

- Session Category: Experimental and Molecular Therapeutics
- Session Title: Agents and Combination for Hematological Malignancies 2
- Session Date & Time: Monday, April 16, 2018; 8:00 AM – 12:00 PM
- Location: McCormick Place South, Exhibit Hall A, Poster Section 38
- Poster Board Number: 20

-- Poster Title: Addition of RP10107, a novel and potent glutaminase inhibitor, accentuates 5-FU activity in lung cancer cell lines in vitro

- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Targets and Inhibitors
- Session Date & Time: Tuesday, April 17, 2018; 1:00 PM – 5:00 PM
- Location: McCormick Place South, Exhibit Hall A, Poster Section 39
- Poster Board Number: 20

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, www.rhizen.com.

Contact:

Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email: kvp@rhizen.com